Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02316678 · ClinicalTrials.gov registry record
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 9,573
- Enrollment target
NCT02316678: Completed study, sponsored by University of Pennsylvania.
NCT02316678 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 9,573 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02316678 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 9,573 participants
- Enrollment target
Study Summary
The investigators will test the hypothesis that that greater efficacy of anti-tumor necrosis factor (antiTNF) therapy results in reduced need for bowel resection surgery, fewer serious infections, and reduced short term mortality risks, and therefore has a more favorable benefit to harm profile than corticosteroids for inflammatory bowel disease.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,573 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02316678
The ClinicalTrials.gov registry entry for NCT02316678 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9,573 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT02316678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02316678 about?
NCT02316678 is a clinical study titled "Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics". The investigators will test the hypothesis that that greater efficacy of anti-tumor necrosis factor (antiTNF) therapy results in reduced need for bowel resection surgery, fewer serious infections, and reduced short term mortality risks, and therefore has a more favorable benefit to harm profile than...
What is the current status of trial NCT02316678?
This trial is currently completed. The enrollment target is 9,573 participants. The study started on 2014-09. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02316678?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT02316678?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.